Comparative Pharmacology
Head-to-head clinical analysis: GRISEOFULVIN versus NUFYMCO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GRISEOFULVIN versus NUFYMCO.
GRISEOFULVIN vs NUFYMCO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to microtubular protein tubulin, disrupting mitotic spindle formation and inhibiting fungal cell mitosis. Also interferes with fungal nucleic acid synthesis and cell wall deposition.
NUFYMCO is a lipid-regulating agent. Its mechanism involves activation of peroxisome proliferator-activated receptor alpha (PPARα), leading to increased lipolysis and elimination of triglyceride-rich particles from plasma, and reduced VLDL production.
500 mg orally once daily or 250 mg orally twice daily; microsize formulation: 500-1000 mg orally once daily; ultramicrosize formulation: 330-375 mg orally once daily. Administer with fatty meal to enhance absorption.
NUFYMCO is a proprietary combination product; standard adult dosing is one capsule (25 mg bempedoic acid/20 mg ezetimibe) orally once daily.
None Documented
None Documented
Clinical Note
moderateGriseofulvin + Estrone sulfate
"The metabolism of Estrone sulfate can be increased when combined with Griseofulvin."
Clinical Note
moderateGriseofulvin + Tranilast
"The risk or severity of adverse effects can be increased when Griseofulvin is combined with Tranilast."
Clinical Note
moderateGriseofulvin + Tolfenamic acid
"The risk or severity of adverse effects can be increased when Griseofulvin is combined with Tolfenamic acid."
Clinical Note
moderateGriseofulvin + Nimesulide
Terminal elimination half-life is 9 to 24 hours; clinically, it allows once or twice daily dosing.
Terminal elimination half-life is 12-15 hours in healthy adults, allowing twice-daily dosing; prolonged to 24-36 hours in moderate renal impairment
Primarily hepatic metabolism; less than 1% excreted unchanged in urine; metabolites excreted in urine (approximately 50%) and feces (approximately 36%) within 24 hours.
Renal (60-70% as unchanged drug), biliary/fecal (20-30% as metabolites and unchanged drug)
Category D/X
Category C
Antifungal
Antifungal
"The risk or severity of adverse effects can be increased when Griseofulvin is combined with Nimesulide."